High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium (DECISION-CAL)

Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination Versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM (DECISION-CAL)

The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.

Study Overview

• Status: Recruiting
• Conditions: Metabolic Syndrome; Dyslipidemias; Coronary Artery Calcification
• Intervention / Treatment: Drug: High intensity statin plus ezetimibe therapy; Drug: Guideline directed statin therapy

Detailed Description

Atherosclerotic cardiovascular diseases (ASCVD), such as myocardial infarction (MI), ischemic stroke, or peripheral arterial disease, are the leading cause of morbidity and mortality worldwide. The causality of low-density lipoproteins cholesterol (LDL-C) level in the development of ASCVD is well demonstrated in previous studies. After introducing LDL-C lowering agents, multiple large-scale randomized clinical trials have demonstrated lower cardiovascular events with lowering LDL-C levels. In particular, for secondary prevention, more aggressive control of LDL-C levels with high-intensity statin therapy significantly reduced cardiovascular events compared with moderate-intensity statin therapy. In addition, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) proved the clinical efficacy of additive ezetimibe for incrementally lowering of LDL-C levels in patients with acute coronary syndrome. However, there has been limited evidence regarding the efficacy and safety of aggressive lipid-lowering strategy using high-intensity statin with a combination of ezetimibe for primary prevention of cardiovascular events among persons without cardiovascular disease. Although the Heart Outcomes Prevention Evaluation (HOPE)-3 and Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials consistently identified that the use of rosuvastatin (10 mg or 20 mg) was significantly associated with reduced future risk of major cardiovascular events in patients who did not have cardiovascular disease, those studies have been focused on the use of statin, not on the intensity of statin.

The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or ASCVD risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD to guide the use of statin or not. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk. Considering that statin has additional properties, including atherosclerotic plaque stabilization, oxidative stress reduction, enhancement of endothelial function, and a decrease in vascular inflammation beyond their lipid-lowering effect, aggressive treatment with a high-intensity statin plus ezetimibe combination might have beneficial effects on the long-term clinical outcomes for asymptomatic patients with significant coronary calcium (Agatston Score ≥ 100) compared with standard lipid-lowering therapy endorsed by the current guidelines.

Therefore, the purpose of DECISION-CALCIUM (Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM) trial is to compare the efficacy and safety of the aggressive lipid-lowering therapy with combination of high-intensity statin and ezetimibe, compared with the current standard lipid-lowering therapy in asymptomatic patients with significant coronary calcification for primary prevention.

• Study Type: Interventional
• Enrollment (Estimated): 6000
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Ki Hong Choi, MD; Phone Number: 82-2-3410-6653; Email: cardiokh@gmail.com
• Study Contact Backup: Name: Seung-Hyuk Choi, MD; Phone Number: 82-2-3410-3419; Email: sh1214.choi@samsung.com

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 06351
    • Recruiting
    • SamsungMedicalCenter
    • Contact: Seunghyuk Choi, PhMD; Phone Number: 82-2-3410-3437

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subject must be at least 40 years of age.
• Asymptomatic patients with presence of coronary calcification (Agatston Score ≥ 100)
• low-density lipoproteins cholesterol (LDL-C) <190 mg/dL

Exclusion Criteria:

• Objective evidence of at least moderate inducible ischemia requiring revascularization treatment
• History of cerebrovascular disease
• History of coronary or peripheral arterial revascularization
• Active liver disease or persistent unexplained serum transaminase elevations more than 2 times the upper limit of normal range
• History of any adverse drug reaction requiring discontinuation of statin (e, g. rhabdomyolysis)
• Allergy or sensitivity to any statin or ezetimibe
• Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine
• Pregnancy or breast feeding
• Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
• Unwillingness or inability to comply with the procedures described in this protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Aggressive treatment arm; In this group, high-intensity statin (rosuvastatin 20mg) combined with ezetimibe 10 mg will be prescribed regardless of patients' age, concomitant diabetes mellitus, or ASCVD risk.	Drug: High intensity statin plus ezetimibe therapy; Rosuvastatin 20 mg + Ezetimibe 10 mg
Active Comparator: Standard treatment arm; In this group, lipid lowering therapy will be followed according to the current guideline recommendation. A moderate-intensity statin (rosuvastatin 5 mg) will be prescribed for patients over 75 years of age or with diabetes mellitus. For non-diabetic patients aged 40-75 years, the use of statins will be determined by calculating the ASCVD risk score. (ASCVD risk <7.5%: no statin use, ≥7.5 - <20%: moderate-intensity statin [rosuvastatin 5mg], ≥ 20%: high-intensity statin [rosuvastatin 20mg])	Drug: Guideline directed statin therapy; At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major adverse cardiovascular events	a composite of death from any causes, myocardial infarction, stroke, unplanned coronary revascularization, or other arterial revascularization procedure	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause death	Death from any causes	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Cardiovascular death	Death from cardiovascular causes	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Stroke	Ischemic or hemorrhagic stroke	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Unplanned coronary revascularization	revascularization procedure to coronary artery	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Arterial revascularization procedure	All arterial revascularization procedure	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Major bleeding	Bleeding Academic Research Consortium (BARC) type 3-5	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Bleeding	BARC type 2-5	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Heart failure hospitalization	Hospitalization due to heart failure	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Coronary calcium progression	Delta CAC	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Changes of LDL-C	Delta LDL-C	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
New-onset diabetes mellitus	Occurence of new-onset diabetes mellitus	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Hepatic disorder requiring discontinuation of statin	Occurence of hepatic disorder requiring discontinuation of statin	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
muscle-related adverse events	Occurence of muscle-related adverse events due to statin	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Proportion of patients with LDL-C < 100mg/dL	Proportion of patients with LDL-C < 100mg/dL	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Proportion of patients with LDL-C < 70mg/dL	Proportion of patients with LDL-C < 70mg/dL	up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

Collaborators and Investigators

• Sponsor: Samsung Medical Center
• Investigators: Principal Investigator: Seung-Hyuk Choi, Samsung Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): July 3, 2023
• Primary Completion (Estimated): June 30, 2029
• Study Completion (Estimated): June 30, 2030

Study Registration Dates

• First Submitted: April 25, 2023
• First Submitted That Met QC Criteria: April 25, 2023
• First Posted (Actual): May 6, 2023

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 12, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Glucose Metabolism Disorders; Insulin Resistance; Hyperinsulinism; Lipid Metabolism Disorders; Metabolic Syndrome; Dyslipidemias; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Other Study ID Numbers: DECISION-CALCIUM

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No